non-alcoholic fatty liver disease (NAFLD)

非酒精性脂肪性肝病 ( NAFLD )
  • 文章类型: Journal Article
    随着与代谢功能障碍相关的脂肪肝的全球患病率上升,这种常见的肝脏疾病与慢性肾脏病(CKD)之间的关联越来越明显.2020年,提出了更具包容性的术语代谢功能障碍相关脂肪性肝病(MAFLD)取代术语非酒精性脂肪性肝病(NAFLD)。观察到的MAFLD和CKD之间的关联以及我们对CKD可能是潜在代谢功能障碍的结果的理解支持了以下观点:与没有MAFLD的人相比,患有MAFLD的人患CKD的风险更高。然而,到目前为止,对于MAFLD患者的CKD没有适当的指导。此外,在肾内科中,很少有人关注MAFLD和CKD之间的联系.
    使用基于Delphi的方法,一个由来自26个国家的50名国际专家组成的多学科小组就一些关于MAFLD和CKD之间联系的公开研究问题达成了共识.
    这份基于德尔菲的共识声明为流行病学提供了指导,机制,MAFLD和CKD的管理和治疗,以及MAFLD的严重程度与CKD风险之间的关系,建立了早期预防和管理这两种常见和相互关联的疾病的框架。
    UNASSIGNED: With the rising global prevalence of fatty liver disease related to metabolic dysfunction, the association of this common liver condition with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the term non-alcoholic fatty liver disease (NAFLD). The observed association between MAFLD and CKD and our understanding that CKD can be a consequence of underlying metabolic dysfunction support the notion that individuals with MAFLD are at higher risk of having and developing CKD compared with those without MAFLD. However, to date, there is no appropriate guidance on CKD in individuals with MAFLD. Furthermore, there has been little attention paid to the link between MAFLD and CKD in the Nephrology community.
    UNASSIGNED: Using a Delphi-based approach, a multidisciplinary panel of 50 international experts from 26 countries reached a consensus on some of the open research questions regarding the link between MAFLD and CKD.
    UNASSIGNED: This Delphi-based consensus statement provided guidance on the epidemiology, mechanisms, management and treatment of MAFLD and CKD, as well as the relationship between the severity of MAFLD and risk of CKD, which establish a framework for the early prevention and management of these two common and interconnected diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    酒精性脂肪性肝炎(ASH)和中度或重度营养不良的肝硬化患者需要肠胃外营养(PN)。当无法进行足够的口服或肠内喂养时,应立即开始PN。ASH和肝硬化患者可以口服或肠内充分喂养,但必须在超过12小时的时间内(包括夜间禁食)放弃食物的人应接受基础葡萄糖输注(2-3g/kg/d)。如果这种禁食期持续超过72小时,则需要总PN。高度肝性脑病(HE)患者的PN;特别是在具有吞咽和咳嗽反射功能障碍的HEIV度,和无保护的气道。肝硬化患者或肝移植后的患者,如果不能充分恢复或肠内营养,应在术后早期接受PN治疗。没有建议通过胃肠外施用谷氨酰胺和精氨酸来调节供体或器官,旨在最小化缺血/再灌注损伤。在急性肝衰竭中,无论营养状态如何,都应考虑人工营养,并且在5至7天内无法重新开始口服营养时,应开始使用人工营养。只要可行,肠内营养应通过鼻十二指肠营养管进行。
    Parenteral nutrition (PN) is indicated in alcoholic steatohepatitis (ASH) and in cirrhotic patients with moderate or severe malnutrition. PN should be started immediately when sufficientl oral or enteral feeding is not possible. ASH and cirrhosis patients who can be sufficiently fed either orally or enterally, but who have to abstain from food over a period of more than 12 hours (including nocturnal fasting) should receive basal glucose infusion (2-3 g/kg/d). Total PN is required if such fasting periods last longer than 72 h. PN in patients with higher-grade hepatic encephalopathy (HE); particularly in HE IV degrees with malfunction of swallowing and cough reflexes, and unprotected airways. Cirrhotic patients or patients after liver transplantation should receive early postoperative PN after surgery if they cannot be sufficiently rally or enterally nourished. No recommendation can be made on donor or organ conditioning by parenteral administration of glutamine and arginine, aiming at minimising ischemia/reperfusion damage. In acute liver failure artificial nutrition should be considered irrespective of the nutritional state and should be commenced when oral nutrition cannot be restarted within 5 to 7 days. Whenever feasible, enteral nutrition should be administered via a nasoduodenal feeding tube.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号